JBJillian Glenda Baker

Jillian Glenda Baker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jillian Glenda Baker has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adrenoceptors in GtoPdb v.2026.3

    by Jillian G. Baker, Dianne Perez, Sergio Parra, Kenneth P. Minneman, Martin C. Michel, Rebecca Hills, J. Paul Hieble, Robert M. Graham, Douglas C. Eikenburg, David B. Bylund, et al.

    The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [140, 358]. Adrenoceptors, α1 There are three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Signalling is predominantly via Gq/11 but α1-adrenoceptors can also couple to Gi/o, Gs and G12/13 [553]. Adrenoceptors are primarily located in blood vessels and in the brain, with the α1A subtype also present in the urogenital tract. Clinical uses: α1-Adrenoceptor antagonists are used to treat hypertension (doxazosin, terazosin [475]), hypertension in pregnancy (labetalol), benign prostatic hyperplasia (alfuzosin, doxazosin, terazosin, tamsulosin and silodosin [347]), PTSD (doxazosin, prazosin) and phaeo-chromocytoma (phenoxybenzamine, phentolamine). α1A-Adrenoceptor agonists are used short-term as nasal decongestants (xylometazoline and oxymetazoline), although they also activate imidazoline and α2A-receptors. Adrenaline and noradrenaline can be given by infusion to treat hypotension in shock. Antagonists: High affinity, non-selective α1-adrenoceptor antagonists include (+)-cyclazosin, doxazosin, prazosin and terazosin. Fluorescent derivatives of prazosin (BODIPY FL-prazosin) are used to examine cellular localisation of α1-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are α1-selective antagonist radioligands. α1A-Subtype selective antagonists include SNAP5089, silodosin, RS-100329 and S(+)-niguldipine (although this also has high affinity for L-type Ca2+ channels). Several anti-depressants and anti-psychotic drugs also have high α1A-adrenoceptor antagonist affinity that may contribute to their CNS actions but likely also contribute to side effects such as orthostatic hypotension [341]. BMY-7378 has α1D-subtype selectivity. Agonists: High efficacy non-selective α1-adrenoceptor agonists include phenylephrine, methoxamine, etilefrine, naphazoline and cirazoline (relative to α2- and β-adrenoceptors). A61603 is selective for the α1A-subtype. Species differences: Very few species differences exist for α1-adrenoceptor ligands. Adrenoceptors, α2 There are three α2-adrenoceptor subtypes α2A, α2B and α2C that are activated by the endogenous agonists (-)-adrenaline and with lower potency by (-)-noradrenaline. α2-Adrenoceptor signalling is predominantly via Gi/o but they can also couple to Gs. α2-Adrenoceptors cause inhibition of voltage dependent Ca2+ channels and augment inwardly rectifying K+ channels [238, 553]. All α2-adrenoceptor subtypes may be located pre- or post-junctionally and are primarily located in brain and kidney with α2A- and α2C- subtypes present in blood vessels and α2A- in spleen and pancreas. Clinical uses: α2-Adrenoceptor antagonists are not used clinically. α2-Adrenoceptor agonists are used to treat hypertension (clonidine, moxonidine, acting via central baroreflex control), to induce analgesia, sedation and anxiolysis (dexmedetomidine), for ADHD (guanfacine), in glaucoma and rosacea (brimonidine (UK14304)) and muscle spasm (tizanidine), as short-term nasal decongestants (xylometazoline and oxymetazoline that also activate imidazoline [119] and α1Areceptors), and increasingly to treat opioid withdrawal. Antagonists: High affinity, non-subtype selective α2-adrenoceptor antagonists include rauwolscine, yohimbine, RX821002, atipamezole and RS79948 [80]. [3H]rauwolscine and [3H]RX821002 are α2-selective antagonist radioligands. BRL44408 has some α2A-selectivity and MK-912 and JP1302 some α2C-selectivity. idazoxan, an early α2-adrenoceptor antagonist, also has significant binding to imidazoline receptors [119] (and 5-HT receptors). Agonists: brimonidine (UK14304) is a high efficacy non-subtype selective α2-adrenoceptor agonist (relative to α1- and β-adrenoceptors). Other agonists include talipexole, apraclonidine (para-amino-clonidine), clonidine, guanfacine, medetomidine and dexmedetomidine. [3H]brimonidine (UK14304) is an α2-selective agonist radioligand. oxymetazoline has significant α2-adrenoceptor agonism, but it is also an α1A and imidazoline receptor agonist [119]. Species differences:There are species variations in the pharmacology of the α2A-adrenoceptor with regard to antagonists although agonist pharmacology is very similar. Adrenoceptors, β There are three β-adrenoceptor subtypes β1, β2 and β3 that are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Signalling is predominantly via Gs, although there are reports of Gi-coupling and ERK1/2 phosphorylation, and the β2-adrenoceptor also activates β-arrestin-mediated signalling [553]. β1-Adrenoceptors are primarily present in heart, blood vessels, kidney and brain; β2-adrenoceptors in lungs, blood vessels, skeletal muscle, heart and brain; and β3-adrenoceptors in the human bladder but also have an important role in rodent brown and white fat. Clinical uses: β-Adrenoceptor antagonists are widely used to treat heart failure, arrhythmias, ischaemic heart disease and hypertension (bisoprolol, carvedilol, metoprolol, nebivolol) [908, 909]. labetalol is used in pregnancy to treat hypertension. β-Adrenoceptor antagonists are also used to treat glaucoma (betaxolol, timolol), anxiety, migraine, benign essential tremor, thyrotoxicosis, portal hypertension and variceal bleeding (propranolol for all). Propranolol is the first line treatment for infantile haemangioma, and there is increasing interest in β-adrenoceptor antagonist use to reduce primary growth and metastasis in cancer [361]. Non-selective β-adrenoceptor agonists are used to treat cardiac arrest and anaphylaxis ((±)-adrenaline), via infusion for shock...

  • Open Access

    Adrenoceptors in GtoPdb v.2026.1

    by Jillian G. Baker, Dianne Perez, Sergio Parra, Kenneth P. Minneman, Martin C. Michel, Rebecca Hills, J. Paul Hieble, Robert M. Graham, Douglas C. Eikenburg, David B. Bylund, et al.

    The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [121, 327]. Adrenoceptors, α1 There are three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Signalling is predominantly via Gq/11 but α1-adrenoceptors can also couple to Gi/o, Gs and G12/13 [505]. Adrenoceptors are primarily located in blood vessels and in the brain, with the α1A subtype also present in the urogenital tract. Clinical uses: α1-Adrenoceptor antagonists are used to treat hypertension (doxazosin, terazosin [436]), hypertension in pregnancy (labetalol), benign prostatic hyperplasia (alfuzosin, doxazosin, terazosin, tamsulosin and silodosin [317]), PTSD (doxazosin, prazosin) and phaeo-chromocytoma (phenoxybenzamine, phentolamine). α1A-Adrenoceptor agonists are used short-term as nasal decongestants (xylometazoline and oxymetazoline), although they also activate imidazoline and α2A-receptors. Adrenaline and noradrenaline can be given by infusion to treat hypotension in shock. Antagonists: High affinity, non-selective α1-adrenoceptor antagonists include (+)-cyclazosin, doxazosin, prazosin and terazosin. Fluorescent derivatives of prazosin (BODIPY FL-prazosin) are used to examine cellular localisation of α1-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are α1-selective antagonist radioligands. α1A-Subtype selective antagonists include SNAP5089, silodosin, RS-100329 and S(+)-niguldipine (although this also has high affinity for L-type Ca2+ channels). Several anti-depressants and anti-psychotic drugs also have high α1A-adrenoceptor antagonist affinity that may contribute to their CNS actions but likely also contribute to side effects such as orthostatic hypotension [312]. BMY-7378 has α1D-subtype selectivity. Agonists: High efficacy non-selective α1-adrenoceptor agonists include phenylephrine, methoxamine, etilefrine, naphazoline and cirazoline (relative to α2- and β-adrenoceptors). A61603 is selective for the α1A-subtype. Species differences: Few species differences have been reported for α1-adrenoceptor ligands. Adrenoceptors, α2 There are three α2-adrenoceptor subtypes α2A, α2B and α2C that are activated by the endogenous agonists (-)-adrenaline and with lower potency by (-)-noradrenaline. α2-Adrenoceptor signalling is predominantly via Gi/o but they can also couple to Gs. α2-Adrenoceptors cause inhibition of voltage dependent Ca2+ channels and augment inwardly rectifying K+ channels [213, 505]. All α2-adrenoceptor subtypes may be located pre- or post-junctionally and are primarily located in brain and kidney with α2A- and α2C- subtypes present in blood vessels and α2A- in spleen and pancreas. Clinical uses: α2-Adrenoceptor antagonists are not used clinically. α2-Adrenoceptor agonists are used to treat hypertension (clonidine, moxonidine, acting via central baroreflex control), to induce analgesia, sedation and anxiolysis (dexmedetomidine), for ADHD (guanfacine), in glaucoma and rosacea (brimonidine (UK14304)) and muscle spasm (tizanidine), as short-term nasal decongestants (xylometazoline and oxymetazoline that also activate imidazoline [101] and α1Areceptors), and increasingly to treat opioid withdrawal. Antagonists: High affinity, non-subtype selective α2-adrenoceptor antagonists include rauwolscine, yohimbine, RX821002, atipamezole and RS79948 [65]. [3H]rauwolscine and [3H]RX821002 are α2-selective antagonist radioligands. BRL 44408 has some α2A-selectivity and MK-912 and JP1302 some α2C-selectivity. idazoxan, an early α2-adrenoceptor antagonist, also has significant binding to imidazoline receptors [101] (and 5-HT receptors). Agonists: brimonidine (UK14304) is a high efficacy non-subtype selective α2-adrenoceptor agonist (relative to α1- and β-adrenoceptors). Other agonists include talipexole, apraclonidine (para-amino-clonidine), clonidine, guanfacine, medetomidine and dexmedetomidine. [3H]brimonidine (UK14304) is an α2-selective agonist radioligand. oxymetazoline has significant α2-adrenoceptor agonism, but it is also an α1A and imidazoline receptor agonist [101]. Species differences:There are species variations in the pharmacology of the α2A-adrenoceptor with regard to antagonists although agonist pharmacology is very similar. Adrenoceptors, β There are three β-adrenoceptor subtypes β1, β2 and β3 that are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Signalling is predominantly via Gs, although there are reports of Gi-coupling and ERK1/2 phosphorylation, and the β2-adrenoceptor also activates β-arrestin-mediated signalling [505]. β1-Adrenoceptors are primarily present in heart, blood vessels, kidney and brain; β2-adrenoceptors in lungs, blood vessels, skeletal muscle, heart and brain; and β3-adrenoceptors in the human bladder but also have an important role in rodent brown and white fat. Clinical uses: β-Adrenoceptor antagonists are widely used to treat heart failure, arrhythmias, ischaemic heart disease and hypertension (bisoprolol, carvedilol, metoprolol, nebivolol) [830, 831]. labetalol is used in pregnancy to treat hypertension. β-Adrenoceptor antagonists are also used to treat glaucoma (betaxolol, timolol), anxiety, migraine, benign essential tremor, thyrotoxicosis, portal hypertension and variceal bleeding (propranolol for all). Propranolol is the first line treatment for infantile haemangioma, and there is increasing interest in β-adrenoceptor antagonist use to reduce primary growth and metastasis in cancer [330]. Non-selective β-adrenoceptor agonists are used to treat cardiac arrest and anaphylaxis ((±)-adrenaline), via infusion for shock...

  • Open Access

    Comparing the Molecular Pharmacological Properties of Existing β‐Blockers to Determine the Theoretically Most “Ideal” Anti‐Cancer β‐Blocker

    by Jillian G. Baker

    There is increasing evidence, from cellular, animal and human epidemiological studies, linking β‐blockers with reductions in cancer growth and metastasis. Propranolol is the most investigated β‐blocker for cancer; although as many different off‐patent β‐blockers exist, there is little commercial incentive to drive comparative clinical trials. To minimize any chance of endogenous β‐agonist driven cancer growth or metastasis, theoretically, the “ideal” anti‐cancer β‐blocker would have high affinity, no partial agonism, and long duration of action at β2‐adrenoceptors (and for some cancers, additionally at β1 or β3‐AR). Using CHO cells stably expressing the wildtype and polymorphic variants of the human β1 and β1‐adrenoceptors, this study assessed 35 β‐blockers for the affinity and duration of binding (using 3 H‐CGP12177 whole cell binding) and intrinsic efficacy (CRE‐gene transcription). Despite high affinity, some β‐blockers had a short binding duration (e.g., alprenolol, bupranolol, levobunolol, nadolol and oxprenolol). Other compounds had substantial partial agonism (e.g., cyanopindolol, bucindolol, pindolol, pronethalol and xamoterol) and other compounds had a biphasic washout (e.g., bucindolol, timolol, carpindolol, and CGP12177) for reasons unknown. Considering all 3 factors, carazolol and ICI118551 may be more “ideal” than propranolol; however, carvedilol, with higher affinity and substantially longer duration of β2 (and β1) receptor binding than propranolol whilst maintaining low partial agonism, may be the most theoretically optimal. Furthermore, it is already widely used in cardiovascular medicine as an off‐patent tablet. Thus, carvedilol may have more optimal molecular pharmacological characteristics for an “anti‐cancer” β‐blocker than propranolol and could enter prospective comparative clinical trials without needing any further clinical workup.


  • Open Access

    Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor

    by Jillian G. Baker, Victor Jun Yu Lim, Richard G.W. Proudman, Franziska N.Z. Giese, Peter Kolb


  • Open Access

    Adrenoceptors in GtoPdb v.2025.3

    by Jillian G. Baker, Dianne Perez, Sergio Parra, Kenneth P. Minneman, Martin C. Michel, Rebecca Hills, J. Paul Hieble, Robert M. Graham, Douglas C. Eikenburg, David B. Bylund, et al.

    The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [116, 324]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and HEAT (BE2254) (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy FLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. α1-Adrenoceptor agonists are used as nasal decongestants; antagonists to treat symptoms of benign prostatic hyperplasia (alfuzosin, doxazosin, terazosin, tamsulosin and silodosin, with the last two compounds being α1A-adrenoceptor selective and claiming to relax bladder neck tone with less hypotension); and to a lesser extent hypertension (doxazosin, terazosin). The α1- and β2-adrenoceptor antagonist carvedilol is used to treat congestive heart failure, although the contribution of α1-adrenoceptor blockade to the therapeutic effect is unclear. Several anti-depressants and anti-psychotic drugs are α1-adrenoceptor antagonists contributing to side effects such as orthostatic hypotension. Adrenoceptors, α2The three α2-adrenoceptor subtypes α2A, α2B and α2C are activated by (-)-adrenaline and with lower potency by (-)-noradrenaline. brimonidine (UK14304) and talipexole are agonists and rauwolscine and yohimbine antagonists selective for α2- relative to α1-adrenoceptors. [3H]rauwolscine, [3H]brimonidine (UK14304) and [3H]RX821002 are relatively selective radioligands. There are species variations in the pharmacology of the α2A-adrenoceptor. Multiple mutations of α2-adrenoceptors have been described, some associated with alterations in function. Presynaptic α2-adrenoceptors regulate many functions in the nervous system. The α2-adrenoceptor agonists clonidine, guanabenz and brimonidine (UK14304) affect central baroreflex control (hypotension and bradycardia), induce hypnotic effects and analgesia, and modulate seizure activity and platelet aggregation. clonidine is an anti-hypertensive (relatively little used) and counteracts opioid withdrawal. dexmedetomidine (also xylazine) is increasingly used as a sedative and analgesic in human [64] and veterinary medicine and has sympatholytic and anxiolytic properties. The α2-adrenoceptor antagonist mirtazapine is used as an anti-depressant. The α2B subtype appears to be involved in neurotransmission in the spinal cord and α2C in regulating catecholamine release from adrenal chromaffin cells. Although subtype-selective antagonists have been developed, none are used clinically and they remain experimental tools. Adrenoceptors, β The three β-adrenoceptor subtypes β1, β2 and β3 are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Isoprenaline is selective for β-adrenoceptors relative to α1- and α2-adrenoceptors, while propranolol (pKi 8.2-9.2) and cyanopindolol (pKi 10.0-11.0) are relatively selective antagonists for β1- and β2- relative to β3-adrenoceptors. (-)-noradrenaline, xamoterol and (-)-Ro 363 show selectivity for β1- relative to β2-adrenoceptors. Pharmacological differences exist between human and mouse β3-adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy at the human β3-adrenoceptor whereas CGP 12177 (low potency) and L 755507 activate human β3-adrenoceptors [88]. β3-Adrenoceptors are resistant to blockade by propranolol, but can be blocked by high concentrations of bupranolol. SR59230A has reasonably high affinity at β3-adrenoceptors, but does not discriminate between the three β- subtypes [520] whereas L-748337 is more selective. [125I]-cyanopindolol, [125I]-hydroxy benzylpindolol and [3H]-alprenolol are high affinity radioligands that label β1- and β2- adrenoceptors and β3-adrenoceptors can be labelled with higher concentrations (nM) of [125I]-cyanopindolol together with β1- and β2-adrenoceptor antagonists. Fluorescent ligands such as BODIPY-TMR-CGP12177 can be used to track β-adrenoceptors at the cellular level [8]. Somewhat selective β1-adrenoceptor agonists (denopamine, dobutamine) are used short term to treat cardiogenic shock but, chronically, reduce survival. β1-Adrenoceptor-preferring antagonists are used to treat cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac failure (metoprolol, nebivolol) but also in combination with other treatments to treat hypertension (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol) [820]. Cardiac failure is also treated with carvedilol that blocks β1- and β2-adrenoceptors, as well as α1-adrenoceptors. Short (salbutamol, terbutaline) and long (formoterol, salmeterol) acting β2-adrenoceptor-selective agonists are powerful bronchodilators used to treat respiratory disorders. Many first generation β-adrenoceptor antagonists (propranolol) block both β1- and β2-adrenoceptors and there are no β2-adrenoceptor-selective antagonists used therapeutically. The β3-adrenoceptor agonist mirabegron is used to control overactive bladder syndrome. There is evidence to suggest that β-adrenoceptor antagonists can reduce metastasis in certain types of cancer [327].


  • Open Access

    A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD

    by Richard G. W. Proudman, Jillian G. Baker

    β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol), long (formoterol, salmeterol), and ultra‐long‐acting (indacaterol, olodaterol, vilanterol) β2‐agonists. Here, the in vitro molecular pharmacological properties of affinity, selectivity, intrinsic efficacy, and duration of β2‐agonists at human β2 and β1‐adrenoceptors and the 4 β2‐polymorphisms stably expressed in CHO cells were directly compared using radioligand binding and functional studies. Whilst short‐acting drugs were similar, there was huge variation and complete overlap in the molecular pharmacological properties of drugs labeled as long and ultra‐long‐acting β2‐agonists. Salmeterol and vilanterol were highly β2‐selective (> 1000‐fold) whereas indacaterol was similar to salbutamol (40‐fold). Formoterol and indacaterol were the most efficacious, whereas salmeterol had the longest duration of binding. Salmeterol and vilanterol utilize a β2‐specific exosite (β2‐H296‐K305) for high affinity and selectivity (that does not affect intrinsic efficacy or duration) whilst the β2‐selectivity of formoterol and olodaterol resides elsewhere. Duration of binding closely correlated with lipophilicity. β2‐polymorphisms had no substantial effect on β2‐agonist properties. Comparison with other β‐ligands suggests that affinity and duration could both be improved further. However, given the very wide range of molecular pharmacological properties of β‐agonists that are clinically effective and widely used, non‐pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) may be as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2‐agonists themselves.


  • Open Access

    A comparison of the molecular pharmacological properties of current short, long and ultra-long-acting β2-agonists used for asthma and COPD.

    by Richard Proudman, Jillian Baker

    [1]¿p#1 Background and purpose β-agonists have been used in asthma for 120 years. There are two recent changes: ultra-long-acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers over short-acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short, long and ultra-long-acting β2-agonists. Experimental approach In vitro molecular pharmacological properties of affinity, selectivity, intrinsic efficacy and duration for β2-agonists at human β2 and β1-adrenoceptors and the 4 β2-polymorphisms were examined using radioligand binding, cAMP and gene transcription. Key results Whilst short-acting β2-agonists were similar, the variation for long and ultra-long-acting β2-agonsits was wide. Salmeterol and vilanterol were highly β2-selective (>1000-fold) whereas indacaterol was similar to salbutamol (40-fold). Formoterol and indacaterol were the most efficacious, whereas salmeterol and vilanterol were the longest acting. Salmeterol and vilanterol utilise a β2-specific exosite (β2-H296-K305) for high affinity and selectivity (that does not affect intrinsic efficacy or duration) whilst the β2-selectivity of formoterol and olodaterol resides elsewhere. Duration of action closely correlated with lipophilicity. β2-polymorphisms had no effect on β2-agonist properties. Conclusion and implications Whilst salbutamol and terbutaline are similar, there was huge variation and complete overlap in the molecular pharmacological properties of long and ultra-long-acting β2-agonists. Whilst affinity and duration could be improved further, given the very wide range of molecular pharmacological properties that are clinically effective and tolerable, non-pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) maybe as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2-agonist themselves.

  • Open Access

    Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed

    by Jillian G Baker, Erica K Sloan, Kevin D G Pfleger, Peter J McCormick, Cristina Salmerón, Paul A Insel

    Survival in pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) at just 5 months is the worst of all cancers. It is predicted to become the second highest cause of cancer deaths worldwide this decade and unlike most cancers, there has been little progress in improving survival in PDAC. Numerous studies including molecular and mechanistic studies, cancer biology studies and retrospective human epidemiological studies suggest that two well-known, approved drug classes — β-blockers and H1-antihistamines — may be beneficial and thus may potentially prolong life in patients with PDAC. In our opinion, the body of evidence has reached a point where the potential gains outweigh the very low risks involved in a clinical study in PDAC. We thus believe that it is now time for a clinical trial involving these two agents in PDAC patients. As a repurposing of generic drugs, this is not likely to be appealing to pharmaceutical companies and therefore is likely to require governmental, philanthropic and /or charitable organisational input. In this article, we opine and propose that an urgent clinical trial is needed to determine if repurposing these two orally administered, inexpensive, largely safe drug classes, either alone or in combination, could prolong survival in PDAC and thus improve the outcome for the 10,000 people worldwide who die from PDAC each week.


  • Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays

    by Jillian G. Baker, Roger J. Summers

    The nine G protein-coupled adrenoceptor subtypes are where the endogenous catecholamines adrenaline and noradrenaline interact with cells. Since they are important therapeutic targets, over a century of effort has been put into developing drugs that modify their activity. This chapter provides an outline of how we have arrived at current knowledge of the receptors, their physiological roles and the methods used to develop ligands. Initial studies in vivo and in vitro with isolated organs and tissues progressed to cell-based techniques and the use of cloned adrenoceptor subtypes together with high-throughput assays that allow close examination of receptors and their signalling pathways. The crystal structures of many of the adrenoceptor subtypes have now been determined opening up new possibilities for drug development.


  • Open Access

    Adrenoceptors in GtoPdb v.2024.2

    by Jillian G. Baker, Dianne Perez, Sergio Parra, Kenneth P. Minneman, Martin C. Michel, Rebecca Hills, J. Paul Hieble, Robert M. Graham, Douglas C. Eikenburg, David B. Bylund, et al.

    The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [116, 324]. Adrenoceptors, α1 The three α1-adrenoceptor subtypes α1A, α1B and α1D are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. -(-)phenylephrine, methoxamine and cirazoline are agonists and prazosin and doxazosin antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and HEAT (BE2254) (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy FLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. α1-Adrenoceptor agonists are used as nasal decongestants; antagonists to treat symptoms of benign prostatic hyperplasia (alfuzosin, doxazosin, terazosin, tamsulosin and silodosin, with the last two compounds being α1A-adrenoceptor selective and claiming to relax bladder neck tone with less hypotension); and to a lesser extent hypertension (doxazosin, terazosin). The α1- and β2-adrenoceptor antagonist carvedilol is used to treat congestive heart failure, although the contribution of α1-adrenoceptor blockade to the therapeutic effect is unclear. Several anti-depressants and anti-psychotic drugs are α1-adrenoceptor antagonists contributing to side effects such as orthostatic hypotension. Adrenoceptors, α2The three α2-adrenoceptor subtypes α2A, α2B and α2C are activated by (-)-adrenaline and with lower potency by (-)-noradrenaline. brimonidine (UK14304) and talipexole are agonists and rauwolscine and yohimbine antagonists selective for α2- relative to α1-adrenoceptors. [3H]rauwolscine, [3H]brimonidine (UK14304) and [3H]RX821002 are relatively selective radioligands. There are species variations in the pharmacology of the α2A-adrenoceptor. Multiple mutations of α2-adrenoceptors have been described, some associated with alterations in function. Presynaptic α2-adrenoceptors regulate many functions in the nervous system. The α2-adrenoceptor agonists clonidine, guanabenz and brimonidine (UK14304) affect central baroreflex control (hypotension and bradycardia), induce hypnotic effects and analgesia, and modulate seizure activity and platelet aggregation. clonidine is an anti-hypertensive (relatively little used) and counteracts opioid withdrawal. dexmedetomidine (also xylazine) is increasingly used as a sedative and analgesic in human [64] and veterinary medicine and has sympatholytic and anxiolytic properties. The α2-adrenoceptor antagonist mirtazapine is used as an anti-depressant. The α2B subtype appears to be involved in neurotransmission in the spinal cord and α2C in regulating catecholamine release from adrenal chromaffin cells. Although subtype-selective antagonists have been developed, none are used clinically and they remain experimental tools. Adrenoceptors, β The three β-adrenoceptor subtypes β1, β2 and β3 are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Isoprenaline is selective for β-adrenoceptors relative to α1- and α2-adrenoceptors, while propranolol (pKi 8.2-9.2) and cyanopindolol (pKi 10.0-11.0) are relatively selective antagonists for β1- and β2- relative to β3-adrenoceptors. (-)-noradrenaline, xamoterol and (-)-Ro 363 show selectivity for β1- relative to β2-adrenoceptors. Pharmacological differences exist between human and mouse β3-adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy at the human β3-adrenoceptor whereas CGP 12177 (low potency) and L 755507 activate human β3-adrenoceptors [88]. β3-Adrenoceptors are resistant to blockade by propranolol, but can be blocked by high concentrations of bupranolol. SR59230A has reasonably high affinity at β3-adrenoceptors, but does not discriminate between the three β- subtypes [520] whereas L-748337 is more selective. [125I]-cyanopindolol, [125I]-hydroxy benzylpindolol and [3H]-alprenolol are high affinity radioligands that label β1- and β2- adrenoceptors and β3-adrenoceptors can be labelled with higher concentrations (nM) of [125I]-cyanopindolol together with β1- and β2-adrenoceptor antagonists. Fluorescent ligands such as BODIPY-TMR-CGP12177 can be used to track β-adrenoceptors at the cellular level [8]. Somewhat selective β1-adrenoceptor agonists (denopamine, dobutamine) are used short term to treat cardiogenic shock but, chronically, reduce survival. β1-Adrenoceptor-preferring antagonists are used to treat cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac failure (metoprolol, nebivolol) but also in combination with other treatments to treat hypertension (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol) [819]. Cardiac failure is also treated with carvedilol that blocks β1- and β2-adrenoceptors, as well as α1-adrenoceptors. Short (salbutamol, terbutaline) and long (formoterol, salmeterol) acting β2-adrenoceptor-selective agonists are powerful bronchodilators used to treat respiratory disorders. Many first generation β-adrenoceptor antagonists (propranolol) block both β1- and β2-adrenoceptors and there are no β2-adrenoceptor-selective antagonists used therapeutically. The β3-adrenoceptor agonist mirabegron is used to control overactive bladder syndrome. There is evidence to suggest that β-adrenoceptor antagonists can reduce metastasis in certain types of cancer [327].